Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9


Novel systemic therapy against malignant pleural mesothelioma.

Mancuso MR, Neal JW.

Transl Lung Cancer Res. 2017 Jun;6(3):295-314. doi: 10.21037/tlcr.2017.06.01. Review.


HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.

Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW.

PLoS One. 2011 Mar 25;6(3):e18198. doi: 10.1371/journal.pone.0018198.


Ribonucleases as potential modalities in anticancer therapy.

Ardelt W, Ardelt B, Darzynkiewicz Z.

Eur J Pharmacol. 2009 Dec 25;625(1-3):181-9. doi: 10.1016/j.ejphar.2009.06.067. Epub 2009 Oct 14. Review.


Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.

Sadiq AA, Patel MR, Jacobson BA, Escobedo M, Ellis K, Oppegard LM, Hiasa H, Kratzke RA.

Invest New Drugs. 2010 Feb;28(1):20-5. doi: 10.1007/s10637-008-9209-1. Epub 2009 Jan 10.


The cytotoxic ribonuclease onconase targets RNA interference (siRNA).

Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z.

Cell Cycle. 2008 Oct;7(20):3258-61. Epub 2008 Oct 25.


Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines.

Ita M, Halicka HD, Tanaka T, Kurose A, Ardelt B, Shogen K, Darzynkiewicz Z.

Cancer Biol Ther. 2008 Jul;7(7):1104-8. Epub 2008 Apr 19.


Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.

Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S, Tassi G, Favoni R, Gaudino G, Mutti L.

Thorax. 2007 Aug;62(8):690-5. Epub 2007 Feb 20.

Supplemental Content

Support Center